CALL - SPRINTER OPEN END - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 01:54:08 2024-07-12 pm EDT | ||
| 20.85 EUR | +2.66% |
|
| Current month | -3.47% | ||
| 1 month | -1.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 20.85 | +2.66% |
| 24-07-11 | 20.31 | -3.05% |
| 24-07-10 | 20.95 | +1.40% |
| 24-07-09 | 20.66 | -2.32% |
| 24-07-08 | 21.15 | +1.20% |
Real-time Boerse Frankfurt Warrants
Last update July 12, 2024 at 01:54 pm EDT
More quotesStatic data
| Product type | Warrant Knock-Out senza Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VP11WK |
| ISIN | DE000VP11WK9 |
| Date issued | 2020-03-27 |
| Strike | 199 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.22 € |
|---|---|
| Lowest since issue | 0.17 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
980.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-2.43%
- Stock Market
- Certificates
- Certificat
